Erich Felber
No más puestos en curso
Origen de la red de primer grado Erich Felber.
Entidad | Tipo de entidad | Industria | |
---|---|---|---|
Micromet AG
Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany.
6
| Extinct | Pharmaceuticals: Major | 6 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Erich Felber a través de su red personal
Empresa | Sector | Personas relacionadas | Puesto principal |
---|---|---|---|
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
MERCK KGAA | Pharmaceuticals: Major | Corporate Officer/Principal | |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Investment Managers | Private Equity Investor | |
Santarus, Inc.
Santarus, Inc. Pharmaceuticals: MajorHealth Technology Santarus, Inc. operates as a biopharmaceutical company. The company was founded on December 6, 1996 and is headquartered in Bridgewater, NJ. | Pharmaceuticals: Major | Director/Board Member | |
NOVARTIS AG | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor | |
MORPHOSYS AG | Biotechnology | Chief Tech/Sci/R&D Officer | |
University of Freiburg | College/University | Corporate Officer/Principal | |
The Scripps Research Institute
The Scripps Research Institute Other Consumer ServicesConsumer Services The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California. | College/University | Corporate Officer/Principal | |
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH Metal FabricationProducer Manufacturing Part of Amgen, Inc., Amgen Research (Munich) GmbH is a biotechnology company based in Munich, Germany. The company has over 850 employees working at two locations in Germany. Amgen Scholars Europe Programs offer practical research experience to 100 students from all over Europe every summer. The company utilizes biotechnological possibilities to develop innovative treatments for diseases. The company continuously develops new substances to provide biopharmaceuticals to patients worldwide with serious illnesses. The CEOs of the company are Peter Kufer and Robert Saller. Amgen Research (Munich was acquired by ECKA Granulate GmbH & Co. KG from Aurubis AG on June 13, 2002. | Metal Fabrication | Chief Tech/Sci/R&D Officer | |
Oxagen Ltd.
Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Sandoz International GmbH
Sandoz International GmbH Pharmaceuticals: GenericHealth Technology Sandoz International GmbH develops and manufactures generic pharmaceuticals. It produces finished dosage forms of such off-patent drugs as diabetes treatment Glucophage, GERD drug Prilosec, and cholesterol. The company was founded in 1996 and is headquartered in Holzkirchen, Austria. | Pharmaceuticals: Generic | Corporate Officer/Principal | |
ABLYNX | Biotechnology | Corporate Officer/Principal | |
The University of Sheffield | College/University | Doctorate Degree | |
TeGenero AG
TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany. | Pharmaceuticals: Major | Director/Board Member | |
University of Gottingen | College/University | Undergraduate Degree | |
Eberhard Karls Universität Tübingen | College/University | Doctorate Degree | |
Freie Universität Berlin | College/University | Doctorate Degree | |
Swiss Federal Institute of Technology | College/University | Doctorate Degree | |
Max-Planck-Institute for Molecular Genetics | College/University | Doctorate Degree | |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Corporate Officer/Principal Director/Board Member Chief Executive Officer Chief Tech/Sci/R&D Officer | |
Ludwig-Maximilians-Universität München | College/University | Doctorate Degree | |
Healthcare Royalty Management LLC
Healthcare Royalty Management LLC Investment ManagersFinance Healthcare Royalty Management LLC (Healthcare Royalty) is a private equity subsidiary of Cowen, Inc. founded in 2007 by Gregory Brown. The firm is headquartered in Stamford, Connecticut. | Investment Managers | Corporate Officer/Principal | |
European Molecular Biology Organization | Corporate Officer/Principal | ||
ISA Pharmaceuticals BV
ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Roche Products Ltd.
Roche Products Ltd. Pharmaceuticals: MajorHealth Technology Roche Products Ltd. manufactures diagnostic, diabetes, and pharmaceutical products. The company was founded on December 14, 1908 and is headquartered in Welwyn Garden City, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
ARGENX SE | Pharmaceuticals: Other | Founder | |
Amgen NV
Amgen NV Pharmaceuticals: MajorHealth Technology Part of Amgen, Inc., Amgen NV is a pharmaceutical company based in Diegem, Belgium. The Belgian company is focused on developing innovative therapies to address serious illnesses and improve the lives of patients. Amgen is committed to advancing scientific research and delivering high-quality medicines to patients worldwide. The CEO of the company is Gabor Sztaniszlav. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Zeneca Pharmaceuticals
Zeneca Pharmaceuticals Pharmaceuticals: MajorHealth Technology Zeneca Pharmaceuticals manufactures medicines. | Pharmaceuticals: Major | Corporate Officer/Principal | |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Biotechnology | Director/Board Member | |
HARPOON THERAPEUTICS, INC. | Biotechnology | Founder | |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Biotechnology | Founder | |
TCR2 THERAPEUTICS INC. | Pharmaceuticals: Major | Founder | |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Biotechnology | Founder | |
Tango Therapeutics Sub, Inc.
Tango Therapeutics Sub, Inc. BiotechnologyHealth Technology Tango Therapeutics, Inc. develops transformational new drugs for cancer patients. The company was founded by Alan Ashworth, Jos? Baselga, Levi Garraway, Timothy K. Lu, Antoni Ribas and William G. Kaelin, Jr. in 2017 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
HOOKIPA PHARMA INC. | Biotechnology | Director/Board Member | |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Pharmaceuticals: Major | Director/Board Member | |
WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder | |
Autolus Holdings (UK) Ltd.
Autolus Holdings (UK) Ltd. BiotechnologyHealth Technology Part of Autolus Therapeutics Plc, Autolus Holdings (UK) Ltd. is a holding British company that operates subsidiaries engaged in pharmaceutical research and development activities. The company is based in London, UK and was founded in 2018. | Biotechnology | Director/Board Member | |
CULLINAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder | |
TANGO THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Crossbow Therapeutics, Inc.
Crossbow Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer |
Estadísticas
Internacional
Estados Unidos | 20 |
Alemania | 15 |
Reino Unido | 10 |
Suiza | 4 |
Bélgica | 3 |
Sectorial
Health Technology | 33 |
Consumer Services | 10 |
Finance | 5 |
Commercial Services | 4 |
Producer Manufacturing | 2 |
Operativa
Director/Board Member | 29 |
Corporate Officer/Principal | 21 |
Chief Tech/Sci/R&D Officer | 10 |
Founder | 9 |
Doctorate Degree | 7 |
Las relaciones más conectadas
Insiders | |
---|---|
Michael Carter | 22 |
Patrick Baeuerle | 19 |
Christian Itin | 12 |
Malte Peters | 11 |
Jens Hennecke | 6 |
Torsten Dreier | 5 |
- Bolsa de valores
- Insiders
- Erich Felber
- Conexiones Empresas